Current report filing

Organization and Principal Activities (Details Narrative) (10-Q)

v3.20.4
Organization and Principal Activities (Details Narrative) (10-Q) - USD ($)
9 Months Ended
Aug. 25, 2020
Sep. 30, 2020
Dec. 31, 2019
Convertible notes payable   $ 849,576
Liabilities   $ 872,687 $ 910
Common shares   500,000 500,000
Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member]      
Percentage of acquisition ownership interest 100.00%    
Percentage of common stock outstanding 75.00%    
Debt tem   1 year  
Percentage of original issuer discount   10.00%  
Debt conversion price   $ 20  
Acquistion valuation cost   $ 12,500,000  
Warrant term   5 years  
Warrant price   $ 30  
Warrant valuation   $ 17,500,000  
Liabilities   $ 3,429,516 $ 3,429,516
Common shares   7,907,351 7,907,351
Share Exchange Agreement [Member] | Sigyn Therapeutics, Inc [Member] | Maximum [Member]      
Convertible notes payable   $ 1,500,000  
Shareholders investment   $ 500,000